Browse MYO6

Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Golgi apparatus, trans-Golgi network membrane; Peripheral membrane protein. Golgi apparatus Nucleus. Cytoplasm, perinuclear region. Membrane, clathrin-coated pit. Cell projection, ruffle membrane; Peripheral membrane protein. Note=Also present in endocyctic vesicles, and membrane ruffles. Translocates from membrane ruffles, endocytic vesicles and cytoplasm to Golgi apparatus, perinuclear membrane and nucleus through induction by p53 and p53-induced DNA damage. Recruited into membrane ruffles from cell surface by EGF-stimulation. Colocalizes with DAB2 in clathrin-coated pits/vesicles. Colocalizes with OPTN at the Golgi complex and in vesicular structures close to the plasma membrane (By similarity). ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasmic vesicle, clathrin-coated vesicle membrane.; SUBCELLULAR LOCATION: Isoform 4: Cytoplasmic vesicle, clathrin-coated vesicle membrane. Cell projection, ruffle membrane.
Domain PF16521 Myosin VI cargo binding domain
PF00063 Myosin head (motor domain)
Function

Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Myosin 6 is a reverse-direction motor protein that moves towards the minus-end of actin filaments. Has slow rate of actin-activated ADP release due to weak ATP binding. Functions in a variety of intracellular processes such as vesicular membrane trafficking and cell migration. Required for the structural integrity of the Golgi apparatus via the p53-dependent pro-survival pathway. Appears to be involved in a very early step of clathrin-mediated endocytosis in polarized epithelial cells. May act as a regulator of F-actin dynamics. May play a role in transporting DAB2 from the plasma membrane to specific cellular targets. Required for structural integrity of inner ear hair cells (By similarity).

> Gene Ontology
 
Biological Process GO:0007605 sensory perception of sound
GO:0030048 actin filament-based movement
GO:0030330 DNA damage response, signal transduction by p53 class mediator
GO:0042493 response to drug
GO:0042770 signal transduction in response to DNA damage
GO:0050954 sensory perception of mechanical stimulus
GO:0072331 signal transduction by p53 class mediator
Molecular Function GO:0000146 microfilament motor activity
GO:0003774 motor activity
GO:0003779 actin binding
GO:0005516 calmodulin binding
GO:0043531 ADP binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051015 actin filament binding
GO:0060001 minus-end directed microfilament motor activity
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0000428 DNA-directed RNA polymerase complex
GO:0001726 ruffle
GO:0005635 nuclear envelope
GO:0005765 lysosomal membrane
GO:0005884 actin filament
GO:0005902 microvillus
GO:0005905 clathrin-coated pit
GO:0005913 cell-cell adherens junction
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016459 myosin complex
GO:0016461 unconventional myosin complex
GO:0016591 DNA-directed RNA polymerase II, holoenzyme
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030880 RNA polymerase complex
GO:0031252 cell leading edge
GO:0031253 cell projection membrane
GO:0031256 leading edge membrane
GO:0031941 filamentous actin
GO:0031965 nuclear membrane
GO:0032587 ruffle membrane
GO:0045177 apical part of cell
GO:0045334 clathrin-coated endocytic vesicle
GO:0055029 nuclear DNA-directed RNA polymerase complex
GO:0061695 transferase complex, transferring phosphorus-containing groups
GO:0098589 membrane region
GO:0098852 lytic vacuole membrane
GO:0098858 actin-based cell projection
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-190873: Gap junction degradation
R-HSA-190828: Gap junction trafficking
R-HSA-157858: Gap junction trafficking and regulation
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-199991: Membrane Trafficking
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MYO6 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MYO6 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MYO6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0190.954
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4150.692
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.3410.651
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.440.203
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.4350.848
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4440.874
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2550.585
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0340.471
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5530.718
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6930.558
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5240.778
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0460.651
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MYO6 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.82.712.10.0439
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.83.411.40.0746
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO6. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO6. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO6.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO6. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MYO6 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MYO6 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMYO6
Namemyosin VI
Aliases KIAA0389; DFNA22; DFNB37; deafness, autosomal recessive 37; myosin-VI; unconventional myosin-6; Unconvention ......
Chromosomal Location6q14.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MYO6 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.